Which antiepileptic drugs (AEDs) work best in combination with levetiracetam (Keppra)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Which AEDs Work Best with Keppra (Levetiracetam)?

Valproate (valproic acid) demonstrates the strongest combination efficacy with levetiracetam based on both clinical evidence and mechanistic rationale, showing similar seizure control rates (68% vs 73%) when used together in refractory status epilepticus 1. Additionally, fosphenytoin/phenytoin, carbamazepine, lamotrigine, and topiramate all combine safely with levetiracetam without pharmacokinetic interactions.

Evidence-Based Combination Recommendations

First-Line Combinations (Strongest Evidence)

Valproate + Levetiracetam:

  • Most extensively studied combination in clinical guidelines 1
  • In refractory status epilepticus after benzodiazepines, valproate achieved 68% seizure cessation vs levetiracetam 73% when used sequentially 1
  • No pharmacokinetic interactions: Valproate 500 mg twice daily does not modify levetiracetam absorption, clearance, or urinary excretion 2
  • Particularly strong enhancement when combined, likely due to complementary GABAergic mechanisms 3
  • Pediatric data shows excellent efficacy: sodium valproate + levetiracetam significantly improved therapeutic outcomes (RR=1.24) and reduced adverse reactions (RR=0.54) compared to monotherapy 4

Fosphenytoin/Phenytoin + Levetiracetam:

  • Level A recommendation: these agents have similar efficacy as second-line treatment after benzodiazepines 5
  • ESETT trial (Class I evidence, 2024): levetiracetam, fosphenytoin, and valproate showed equivalent efficacy (~47% seizure cessation) 5
  • No pharmacokinetic interactions: Levetiracetam 3000 mg daily has no effect on phenytoin disposition, and phenytoin doesn't affect levetiracetam 2
  • Hypotension risk slightly higher with fosphenytoin (3.2%) vs levetiracetam (0.7%) 5

Second-Line Combinations (Good Safety Profile)

Carbamazepine + Levetiracetam:

  • No pharmacokinetic interactions documented 2
  • Levetiracetam does not influence carbamazepine plasma concentrations 2
  • Important caveat: Enzyme-inducing AEDs like carbamazepine increase levetiracetam clearance by ~22% in pediatric patients, though dose adjustment is not recommended 2
  • Preclinical safety data: levetiracetam 250 mg/kg + carbamazepine 50 mg/kg did NOT induce neurodegeneration in developing rat brains, unlike other combinations 6

Lamotrigine + Levetiracetam:

  • No pharmacokinetic interactions 2
  • Levetiracetam has no effect on lamotrigine plasma concentrations 2
  • Both recommended as first-choice AEDs in neuro-oncology due to efficacy and tolerability 7
  • Common pairing in clinical practice for focal epilepsy 8

Topiramate + Levetiracetam:

  • No pharmacokinetic interactions 2
  • Levetiracetam does not affect topiramate concentrations 2
  • Sodium valproate + levetiracetam showed better outcomes than sodium valproate + topiramate in pediatric epilepsy 4

Combinations to Approach with Caution

Lacosamide + Levetiracetam:

  • Emerging combination with complementary mechanisms 9
  • Both have novel mechanisms of action
  • May assume larger role as add-on treatment 7
  • Limited long-term safety data compared to traditional combinations

Key Mechanistic Advantages

Why levetiracetam combines well with other AEDs:

  • No cytochrome P450 interactions: Levetiracetam is neither an inhibitor nor substrate of liver enzymes 2
  • Minimal protein binding (<10%): No competition for binding sites 2
  • Novel mechanism: SV2A modulation complements traditional mechanisms (sodium channels, GABA enhancement, glutamate reduction) 3
  • Universal enhancement: Preclinical data shows levetiracetam enhances protective activity of most AEDs without exacerbating side effects 3

Clinical Pitfalls to Avoid

  1. Enzyme-inducing AEDs (carbamazepine, phenytoin, phenobarbital): While safe to combine, they increase levetiracetam clearance by ~22% in children 2. Monitor for reduced efficacy but dose adjustment typically not needed.

  2. Avoid phenobarbital combinations in pregnancy/neonates: Unlike levetiracetam + carbamazepine, other combinations may cause neurodegeneration in developing brains 6

  3. Don't assume home AED matters: In status epilepticus, using the patient's home medication as second-line agent does not affect seizure cessation probability 5

  4. Psychiatric side effects: Levetiracetam can cause behavioral changes (aggression, depression, psychosis) 2. This risk may be relevant when combining with other AEDs affecting mood.

Practical Algorithm for Combination Selection

For status epilepticus (after benzodiazepines):

  • Choose ANY of: levetiracetam, fosphenytoin, or valproate—all equally effective 5
  • If hypotension concern: prefer levetiracetam (0.7% risk) over fosphenytoin (3.2% risk) 5

For chronic epilepsy management:

  1. First choice: Valproate + levetiracetam (strongest preclinical synergy, excellent pediatric data) 3, 4
  2. If valproate contraindicated (pregnancy, liver disease): Lamotrigine or carbamazepine + levetiracetam 2
  3. If GABAergic enhancement desired: Combine with valproate or other GABA-enhancing agents 3
  4. Brain tumor patients: Levetiracetam + lamotrigine preferred (avoid enzyme-inducers) 7

Drug interactions requiring no dose adjustment:

  • Oral contraceptives, digoxin, warfarin: all safe with levetiracetam 2
  • Probenecid: doubles metabolite levels but doesn't affect parent drug efficacy 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.